Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes

Hunger, 2015, Acute lymphoblastic leukemia in children., N Engl J Med., 373, 1541, 10.1056/NEJMra1400972

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia., N Engl J Med., 371, 1507, 10.1056/NEJMoa1407222

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial., Lancet., 385, 517, 10.1016/S0140-6736(14)61403-3

Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults., Blood., 129, 3322, 10.1182/blood-2017-02-769208

Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia., N Engl J Med., 378, 439, 10.1056/NEJMoa1709866

Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia., Sci Transl Med., 5, 10.1126/scitranslmed.3005930

Sadelain, 2013, The basic principles of chimeric antigen receptor design., Cancer Discov., 3, 388, 10.1158/2159-8290.CD-12-0548

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia., Sci Transl Med., 3, 10.1126/scitranslmed.3002842

Kochenderfer, 2011, Chimeric antigen receptor-modified T cells in CLL., N Engl J Med., 365, 1937, 10.1056/NEJMc1111004

Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma., N Engl J Med., 377, 2531, 10.1056/NEJMoa1707447

Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia., N Engl J Med., 378, 449, 10.1056/NEJMoa1709919

Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia., N Engl J Med., 365, 725, 10.1056/NEJMoa1103849

Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients., J Clin Invest., 126, 2123, 10.1172/JCI85309

Brentjens, 2007, Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts., Clin Cancer Res., 13, 5426, 10.1158/1078-0432.CCR-07-0674

Imai, 2004, Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia., Leukemia., 18, 676, 10.1038/sj.leu.2403302

Majzner, 2018, Tumor antigen escape from CAR T-cell therapy., Cancer Discov., 8, 1219, 10.1158/2159-8290.CD-18-0442

Schultz, 2019, Mechanisms of and approaches to overcoming resistance to immunotherapy., Hematol Am Soc Hematol Educ Program., 2019, 226, 10.1182/hematology.2019000018

Sotillo, 2015, Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy., Cancer Discov., 5, 1282, 10.1158/2159-8290.CD-15-1020

Orlando, 2018, Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia., Nat Med., 24, 1504, 10.1038/s41591-018-0146-z

Gardner, 2016, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy., Blood., 127, 2406, 10.1182/blood-2015-08-665547

Jacoby, 2016, CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity., Nat Commun., 7, 10.1038/ncomms12320

Finney, 2019, CD19 CAR T cell product and disease attributes predict leukemia remission durability., J Clin Invest., 129, 2123, 10.1172/JCI125423

Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors., Nat Med., 21, 581, 10.1038/nm.3838

Annesley, 2019, Novel CD19t T-antigen presenting cells expand CD19 CAR T cells in vivo., Blood., 10.1182/blood-2019-131346

Li, 2018, Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia., Blood., 10.1182/blood-2018-99-112572

Singh, 2016, Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies., Sci Transl Med., 8, 10.1126/scitranslmed.aad5222

Eyquem, 2017, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection., Nature., 543, 113, 10.1038/nature21405

Lynn, 2019, c-Jun overexpression in CAR T cells induces exhaustion resistance., Nature., 576, 293, 10.1038/s41586-019-1805-z

Feucht, 2019, Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency., Nat Med., 25, 82, 10.1038/s41591-018-0290-5

Majzner, 2020, Tuning the antigen density requirement for CAR T-cell activity., Cancer Discov., 10, 702, 10.1158/2159-8290.CD-19-0945

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia., Sci Transl Med., 6, 10.1126/scitranslmed.3008226

Lee, 2018, asbmt consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells., Biol Blood Marrow Transplant., 25

Pennisi, 2020, Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management., Blood Adv., 4, 676, 10.1182/bloodadvances.2019000952

Neelapu, 2018, Chimeric antigen receptor T-cell therapy–assessment and management of toxicities., Nat Rev Clin Oncol., 15, 47, 10.1038/nrclinonc.2017.148

Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia., Cancer Discov., 6, 664, 10.1158/2159-8290.CD-16-0040

Shah, 2020, CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I Anti-CD22 CAR T-cell trial., J Clin Oncol., 38, 10.1200/JCO.19.03279

Laetsch, 2020, Immunoglobulin replacement and quality of life after CAR T-cell therapy–Authors’ reply., Lancet Oncol., 21, 10.1016/S1470-2045(19)30814-9

Hill, 2019, CAR-T–and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy., Blood Rev., 38, 10.1016/j.blre.2019.100596

Jacoby, 2019, The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia., Bone Marrow Transplant., 54, 810, 10.1038/s41409-019-0604-3

Lee, 2016, Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation., Blood., 128, 218, 10.1182/blood.V128.22.218.218

Hay, 2019, Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy., Blood., 133, 1652, 10.1182/blood-2018-11-883710

Summers, 2018, Long term follow-up after SCRI-CAR19v1 reveals late recurrences as well as a survival advantage to consolidation with HCT after CAR T cell induction remission., Blood., 32, 967, 10.1182/blood-2018-99-115599